Jazz Pharmaceuticals company profile

JAZZ · NASDAQ · USD

Compare Jazz Pharmaceuticals
$240.71Change from previous close: +0.39%Absolute change: +$0.94

Close · November 17, 2026

Company profile

Jazz Pharmaceuticals has 2,890 employees and is headquartered in Dublin, Ireland.

Sales are concentrated in the United States, which generated 89.8% of revenue, while Europe contributed 8.0% and other countries 2.2%. The company identifies, develops and commercializes pharmaceutical products, with Xywav treating narcolepsy and idiopathic hypersomnia, Epidiolex treating seizures linked to rare epilepsy syndromes, and Rylaze and Enrylaze treating acute lymphoblastic leukemia. Its oncology range also includes Zepzelca for small cell lung cancer, Ziihera for biliary tract cancers and Modeyso for diffuse midline glioma. Pipeline programs cover zanidatamab, dordaviprone and Vyxeos in further indications, and the company works with partners such as Zymeworks and Sumitomo Pharma.

In the fiscal year ended December 2025, revenue reached 4.3 billion US dollars, up 4.9% from the previous year, while the company posted a net loss of 356.1 million dollars. Jazz Pharmaceuticals has 2,890 employees, and its headquarters are in Dublin, Ireland. The company dates from 2003.

Company facts

Industry
Biotechnology
Headquarters
Waterloo Exchange, D04 E5W7, Dublin
Employees
2,890
Chief executive
Renee Gala
Founded
2003
Fiscal year
January - December
Listing
JAZZ · NASDAQ
Currency
USD
ISIN
IE00B4Q5ZN47

Jazz Pharmaceuticals and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
Jazz PharmaceuticalsJAZZUnited States$15.5B2,89027.4%71.5
BridgeBio PharmaBBIOUnited States$15.25B1,081-37.3%—
ExelixisEXELUnited States$16.37B1,07740.2%20.1
Halozyme TherapeuticsHALOUnited States$14.67B42356.8%38.3
Ascendis PharmaASNDUnited States$18.06B1,18930.9%18.1
Bio-TechneTECHUnited States$11.43B3,00021.7%66.8

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Jazz Pharmaceuticals with its competitors